看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。4 D# j! R+ k' n
& \2 q1 E4 a! v3 E' Y0 e! p
3 e0 a: [8 O+ t* oCurrently available feasibility data for possible combination strategies.
. D* H0 r% E; e8 D- F; `1 `' h+ A————————————————————————————————
% G3 Z9 c+ t4 M9 w# ACombination Feasibility according to preliminary data # g8 @6 i3 T8 ~4 O r
——————————————————————————————————
# x* Y) E. S, r fBevacizumab + sorafenib Yes, reduced dose 2 I" | ^' c5 `+ x, y
Bevacizumab + sunitinib† No
2 N% P& e% u# \( rBevacizumab + temsirolimus Yes 0 U: r" G1 e- k+ F; l; S6 q$ O- w/ B
Bevacizumab + everolimus Yes + ]( P3 D6 ], ^8 S" A7 F8 s& S
Sorafenib + sunitinib ? & w3 R& w" M2 f. i# T/ z: i
Sorafenib + temsirolimus Yes, reduced dose - Y5 V8 |+ e" ~1 M
Sorafenib + everolimus Yes, reduced dose 2 K& g3 e% x8 _8 e. v E
Sunitinib + temsirolimus† No % R, a P* [7 a T
Sunitinib + everolimus ?
% e2 K1 |3 {/ I6 h @9 gTemsirolimus + everolimus ? ) w6 N3 L' U+ E8 j, S3 H3 x8 [
————————————————————: p- ~" O O; A! w5 H8 B
†Led to US FDA warning.
% m: m% a& R* [( d/ }, m?: As yet unattempted combination.7 T' O( e* K- n7 b5 N
|